Business
Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights
- Recent biomarker data identifies a simple blood test that may predict clinical respons...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights- Recent biomarker data identifies a simple blood test that may predict clinical response to pelareorep -- Interim data from ongoing AWARE-1 window of opportunity breast cancer study expected in 2H 2019 -CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 3, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2019. All dollar amounts are expressed in Canadian currency unless otherwise noted.''Our primary focus remains the breast cancer program and the timely completion of our AWARE-1 study of pelareorep in combination with the immune checkpoint inhibitor Tecentriq. We remain on track to report interim data in the second half of this year,'' said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. ''We expect the results of this important study to confirm the clinical utility of using T cell clonality as a biomarker for patient response to pelareorep, as well as pelareorep's ability to prime the immune system to recognize cancer cells and enhance the potential efficacy of checkpoint inhibitors. This data will assist in the final design of our registrational study of pelareorep as a treatment for metastatic breast cancer and serve to confirm the broader utility of this biomarker, currently established in pancreatic cancer and multiple myeloma, across multiple cancer types.''Selected highlights since January 1, 2019Clinical & Scientific Updates Announced the identification of T cell clonality as a potentially predictive and prognostic biomarker of pelareorep therapy in a poster presentation delivered at the American Association for Cancer Research 2019 annual meeting Treated the first patient in the AWARE-1 window of opportunity study, which is being conducted in collaboration with SOLTI, in which patients will receive the appropriate intervention for their breast cancer sub-type plus pelareorep with or without Roche's anti PD-L1 Tecentriq®, followed by surgery Published data in the journal Blood Advances highlighting the synergistic effect of pelareorep in combination with proteasome inhibitor bortezomib for the treat...